Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker

European Heart Journal

Volumn 23, Issue 3, 2002, Pages 239-246

  Ronner, E ^a   Boersma, E ^a   Akkerhuis, K M ^a   Harrington, R A ^b   Lincoff, A M ^c   Deckers, J W ^a   Karsch, K ^d   Kleiman, N S ^e   Vahanian, A ^f   Topol, E J ^c   Califf, R M ^b   Simoons, Maarten L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f HÔPITAL TENON   (France)

Author keywords

Acute coronary syndromes; Eptifibatide; Myocardial infarction; Platelet aggregation inhibitors; Revascularization; Unstable angina pectoris

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY DISEASE; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PLACEBOS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; POSTOPERATIVE COMPLICATIONS; SURVIVAL ANALYSIS; SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036488099     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2736     Document Type: Article

References (26)

1. Braunwald E, Jones RH, Mark DB et al. Diagnosing and managing unstable angina. Circulation 1994; 90: 613-22.
2. Hillis WS. The continuing debate: conservative or interventional therapy for unstable coronary artery disease. Am J Cardiol 1997; 80: 51E-54E.
3. Theroux P, Fuster V. Acute coronary syndromes. Unstable angina and non-Q myocardial infarction. Circulation 1998; 97: 1195-206.
4. Theroux P, White H, David D et al. for the TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation 1994; 89: 1545-56.
5. Boden WE, O'Rourke RA, Crawford MH et al. Outcomes in patients with acute non-Q myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998; 338: 1785-92.
6. The Fragmin and Fast Revascularization during Instability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: Frisc II prospective randomised multicentre study. Lancet 1999; 354: 708-15.
7. TACTICS TIMI-18 results were presented during the November 2000 annual sessions of the American Heart Association.
8. Van Miltenburg-Van Zijl AJM, Simoons ML, Bossuyt PMM, Taylor TR, Veerhoek MJ. Variation in the use of coronary angiography in patients with unstable angina is related to differences in patient population and availability of angiography facilities, without affecting prognosis. Eur Heart J 1996; 17: 1828-35.
9. Yusuf S, Flather M, Pogue J et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Lancet 1998; 352: 507-14.
10. De Feyter PJ, Suryapranata H, Serruys PW et al. Coronary Angioplasty for Unstable Angina: Immediate and Late Results in 200 Consecutive Patients With Identification of Risk Factors for Unfavorable Early and Late Outcome. J Am Coll Cardiol 1988; 12: 324-33.
11. Bentivoglio LG, Detre K, Yeh W, Williams DO, Kelsey SF, Faxon DP. Outcome of percutaneous transluminal coronary angioplasty in subsets of unstable angina pectoris. A report of the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1994; 24: 1195-206.
12. Boersma E, Akkerhuis M, Theroux P. Platelet glycoprotein IIb/IIIa receptor inhibition in Non-ST-Elevation acute coronary syndromes. Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999; 100: 2045-8.
13. Ronner E, Dykun Y, Van den Brand MJBM, Van der Wieken LR, Simoons ML. Platelet glycoprotein IIb/IIIa receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Eur Heart J 1998; 19: 1608-16.
14. The PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
15. Harrington RA. Clinical trials in acute coronary syndromes: lessons from PURSUIT. Eur Heart J 1999; 1 (Suppl R): R28-R34.
16. Boersma E, Pieper KS, Steyerberg EW et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. Circulation 2000; 101: 2557-67.
17. Bertrand ME, Simoons ML, Fox KAA et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST-segment elevation. Recommendations of the task force of the European Society of Cardiology. Eur Heart J 2000; 17: 1406-32.
18. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the ACC/AHA task force on practice guidelines. Circulation 2000; 102: 1193-2009.
19. Cohen M, Demers C, Gurfinkel EP et al., for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary disease. N Engl J Med 1997; 337: 447-52.
20. The FRISC Study Group (Fragmin during instability in coronary artery disease study group). Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-8.
21. Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction. Circulation 1999; 100: 1593-601.
22. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
23. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
24. The EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled rial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
25. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-35.
26. The ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised placebo-controlled trial. Lancet 2000; 356: 2037-44.